TY - JOUR
T1 - Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions
AU - Russick, Jules
AU - Joubert, Pierre Emmanuel
AU - Gillard-Bocquet, Mélanie
AU - Torset, Carine
AU - Meylan, Maxime
AU - Petitprez, Florent
AU - Dragon-Durey, Marie Agnes
AU - Marmier, Solenne
AU - Varthaman, Aditi
AU - Josseaume, Nathalie
AU - Germain, Claire
AU - Goc, Jérémy
AU - Dieu-Nosjean, Marie Caroline
AU - Validire, Pierre
AU - Fournel, Ludovic
AU - Zitvogel, Laurence
AU - Bindea, Gabriela
AU - Lupo, Audrey
AU - Damotte, Diane
AU - Alifano, Marco
AU - Cremer, Isabelle
N1 - Publisher Copyright:
©
PY - 2020/10/16
Y1 - 2020/10/16
N2 - Background Natural killer (NK) cells play a crucial role in tumor immunosurveillance through their cytotoxic effector functions and their capacity to interact with other immune cells to build a coordinated antitumor immune response. Emerging data reveal NK cell dysfunction within the tumor microenvironment (TME) through checkpoint inhibitory molecules associated with a regulatory phenotype. Objective We aimed at analyzing the gene expression profile of intratumoral NK cells compared with non-tumorous NK cells, and to characterize their inhibitory function in the TME. Methods NK cells were sorted from human lung tumor tissue and compared with non- tumoral distant lungs. Results In the current study, we identify a unique gene signature of NK cell dysfunction in human non-small cell lung carcinoma (NSCLC). First, transcriptomic analysis reveals significant changes related to migratory pattern with a downregulation of sphingosine-1-phosphate receptor 1 (S1PR1) and CX3C chemokine receptor 1 (CX3CR1) and overexpression of C-X-C chemokine receptor type 5 (CXCR5) and C-X-C chemokine receptor type 6 (CXCR6). Second, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and killer cell lectin like receptor (KLRC1) inhibitory molecules were increased in intratumoral NK cells, and CTLA-4 blockade could partially restore MHC class II level on dendritic cell (DC) that was impaired during the DCs/NK cell cross talk. Finally, NK cell density impacts the positive prognostic value of CD8 + T cells in NSCLC. Conclusions These findings demonstrate novel molecular cues associated with NK cell inhibitory functions in NSCLC.
AB - Background Natural killer (NK) cells play a crucial role in tumor immunosurveillance through their cytotoxic effector functions and their capacity to interact with other immune cells to build a coordinated antitumor immune response. Emerging data reveal NK cell dysfunction within the tumor microenvironment (TME) through checkpoint inhibitory molecules associated with a regulatory phenotype. Objective We aimed at analyzing the gene expression profile of intratumoral NK cells compared with non-tumorous NK cells, and to characterize their inhibitory function in the TME. Methods NK cells were sorted from human lung tumor tissue and compared with non- tumoral distant lungs. Results In the current study, we identify a unique gene signature of NK cell dysfunction in human non-small cell lung carcinoma (NSCLC). First, transcriptomic analysis reveals significant changes related to migratory pattern with a downregulation of sphingosine-1-phosphate receptor 1 (S1PR1) and CX3C chemokine receptor 1 (CX3CR1) and overexpression of C-X-C chemokine receptor type 5 (CXCR5) and C-X-C chemokine receptor type 6 (CXCR6). Second, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and killer cell lectin like receptor (KLRC1) inhibitory molecules were increased in intratumoral NK cells, and CTLA-4 blockade could partially restore MHC class II level on dendritic cell (DC) that was impaired during the DCs/NK cell cross talk. Finally, NK cell density impacts the positive prognostic value of CD8 + T cells in NSCLC. Conclusions These findings demonstrate novel molecular cues associated with NK cell inhibitory functions in NSCLC.
KW - CTLA-4 antigen
KW - Natural Killer T-Cells
KW - biomarkers
KW - lung neoplasms
KW - tumor
KW - tumor microenvironment
UR - http://www.scopus.com/inward/record.url?scp=85093705821&partnerID=8YFLogxK
U2 - 10.1136/jitc-2020-001054
DO - 10.1136/jitc-2020-001054
M3 - Article
C2 - 33067317
AN - SCOPUS:85093705821
SN - 2051-1426
VL - 8
JO - Journal for ImmunoTherapy of Cancer
JF - Journal for ImmunoTherapy of Cancer
IS - 2
M1 - e001054
ER -